# OnCo record paper-viale-a-venetoclax-azacitidine-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-viale-a-venetoclax-azacitidine-nejm-2020" ;
  schema:name "VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy"@en ;
  schema:description "Adding the BCL-2 inhibitor venetoclax to azacitidine more than doubled remission rates and extended median survival from 9.6 to 14.7 months in unfit AML patients."@en ;
  schema:url <https://onco.cc/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2012971>, <https://clinicaltrials.gov/study/NCT02993523> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2012971> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "DiNardo CD, Jonas BA, Pullarkat V, et al." ;
  onco:related <https://onco.cc/pairings/venetoclax-plus-hma/>, <https://onco.cc/pairings/menin-plus-venetoclax-hma/> ;
  onco:cancers <https://onco.cc/cancers/aml/> ;
  onco:targets <https://onco.cc/targets/bcl2/> ;
  onco:drugs <https://onco.cc/drugs/venetoclax/>, <https://onco.cc/drugs/azacitidine/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:terms <https://onco.cc/terms/os/>, <https://onco.cc/terms/mrd-negative-cr/> ;
  onco:trials <https://onco.cc/trials/viale-a/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-aging-comorbidity/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:journals <https://onco.cc/journals/nejm/> .